Transforming Factor Beta Receptor 2 (TGFBR2) is a single-pass transmembrane serine/threonine kinase receptor that plays a critical role in the TGF-beta signaling pathway. Upon binding its ligands (TGFB1, TGFB3), TGFBR2 phosphorylates and activates TGFBR1, initiating downstream SMAD2/3 signaling. In the tumor microenvironment (TME), hyperactivation of this pathway drives immunosuppression, epithelial-to-mesenchymal transition (EMT), metastasis, and drug resistance. Consequently, TGFBR2 has emerged as a premier target for oncology therapeutics, particularly through bifunctional fusion proteins (e.g., TGF-beta traps fused to immune checkpoint inhibitors) and bispecific antibodies.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TGFBR2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TGFBR2 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View TGFBR2 Products |
| Gene Delivery | TGFBR2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View TGFBR2 Products |
| Benchmark Ab | Anti-TGFBR2 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View TGFBR2 Products |
| Validator | TGFBR2 siRNA Set Target-specific siRNA pool for knockdown verification and target specificity validation. |
View TGFBR2 Products |
| Related Target A | TGFB1 Primary ligand for TGFBR2; critical for establishing ligand-receptor binding and trap-efficiency assays. |
View TGFB1 Products |
| Related Target B | TGFBR1 Downstream kinase partner; essential for heterodimerization assays and pathway blockade screening. |
View TGFBR1 Products |
| Related Target C | PD-L1 (CD274) Primary synergistic partner for bifunctional fusion proteins (e.g., Y-traps / Bintrafusp-alfa biosimilars). |
View PD-L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand-Trapping Quantification | HEK293-expressed TGFBR2 ECD-Fc provides native post-translational modifications, ensuring accurate binding kinetics in SPR/BLI assays. |
| Cross-Species Toxicity Screening | Human, Mouse, and Cynomolgus ortholog proteins strictly verified by mass spectrometry to support preclinical safety profiling. |
| Lack of Validated Controls | Sequence-verified clinical benchmark antibodies included to establish reliable assay baselines. |
| Off-Target False Positives | Sequence-verified siRNA sets included to confirm target-specific signaling knockdown. |
Live TGFBR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TGFBR2 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to bifunctional fusion proteins (TGF-beta traps) and bispecific antibodies. While first-generation systemic TGF-beta inhibitors faced narrow therapeutic windows due to cardiotoxicity, the next wave of R&D is targeting localized activation within the tumor microenvironment (TME). By pairing TGFBR2 extracellular domains with tumor-targeting or checkpoint-blocking moieties (such as anti-PD-L1 or anti-EGFR), drug developers are achieving localized TGF-beta suppression, minimizing systemic adverse events while maximizing anti-tumor immunity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bifunctional Fusion (Trap) | Merck KGaA, GSK, Hengrui Medicine | NSCLC, Biliary Tract Cancer, HPV+ Cancers | Simultaneous binding assays (Requires high-purity TGFBR2 ECD-Fc and PD-L1 antigens) |
| Bispecific Antibody | Sanofi, Alphamab Oncology | Solid Tumors, Colorectal Cancer | Heterodimer validation and cross-reactivity screening (Requires Human/Cyno ortholog proteins) |
| CAR-T (Dominant Negative) | Academic Institutions, Biotech Startups | Prostate Cancer, Glioblastoma | Stable cell line construction to verify TGF-beta resistance (Requires Lentivirus Premade Particles) |